Some studies have reported that serum levels of MUC1 (mucin 1, also called KL-6) and vascular endothelial growth factor (VEGF) are associated with tumor response, progression-free survival (PFS) and overall survival (OS) in NSCLC patients treated with EGFR-TKIs [16, 17]. This evidence concerns the gene VEGFA and neoplasm.